[
  {
    "ts": null,
    "headline": "Quest Diagnostics Declares Quarterly Cash Dividend",
    "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025.",
    "url": "https://finnhub.io/api/news?id=7b85a9b5fdf523201d73e6d267062f0ca7cfac14e7b03ef0d311133691580d01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747261020,
      "headline": "Quest Diagnostics Declares Quarterly Cash Dividend",
      "id": 134461575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025.",
      "url": "https://finnhub.io/api/news?id=7b85a9b5fdf523201d73e6d267062f0ca7cfac14e7b03ef0d311133691580d01"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 21, 2025",
    "summary": "Quest Diagnostics announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on...",
    "url": "https://finnhub.io/api/news?id=3d7cd5c04232b728f58630c798537d7e61ecf6bed71cf362c6869ae4518f5fb9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747246620,
      "headline": "Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 21, 2025",
      "id": 134459640,
      "image": "",
      "related": "DGX",
      "source": "Finnhub",
      "summary": "Quest Diagnostics announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on...",
      "url": "https://finnhub.io/api/news?id=3d7cd5c04232b728f58630c798537d7e61ecf6bed71cf362c6869ae4518f5fb9"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fdb56c3aab46cb0982f8293da26902a47d9a264a9b525aeb7ff0df85132de37e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747242480,
      "headline": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134482732,
      "image": "",
      "related": "DGX",
      "source": "MarketWatch",
      "summary": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fdb56c3aab46cb0982f8293da26902a47d9a264a9b525aeb7ff0df85132de37e"
    }
  },
  {
    "ts": null,
    "headline": "GRAIL Inc (GRAL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances",
    "summary": "GRAIL Inc (GRAL) reports a 19% revenue increase and significant progress in clinical trials, despite facing competitive challenges and a substantial net loss.",
    "url": "https://finnhub.io/api/news?id=52527fd4e11dc78780d55f5b09a4fde857a2ea841062cab9e8b9b866ce4bb538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747207093,
      "headline": "GRAIL Inc (GRAL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances",
      "id": 134461577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "GRAIL Inc (GRAL) reports a 19% revenue increase and significant progress in clinical trials, despite facing competitive challenges and a substantial net loss.",
      "url": "https://finnhub.io/api/news?id=52527fd4e11dc78780d55f5b09a4fde857a2ea841062cab9e8b9b866ce4bb538"
    }
  }
]